H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
As a result of superior efficacy and overall tolerability, atypical antipsychotic drugs have become the treatment of choice for schizophrenia and related disorders, despite their side effects. Weight gain is a common and potentially serious complication of some antipsychotic drug therapy, and may be accompanied by hyperlipidemia, hypertension and hyperglycemia and, in some extreme cases, diabetic ketoacidosis. The molecular mechanism(s) responsible for antipsychotic drug-induced weight gain are unknown, but have been hypothesized to be because of interactions of antipsychotic drugs with several neurotransmitter receptors, including 5-HT(2A) and 5-HT(2C) serotonin receptors, H(1)-histamine receptors, alpha(1)- and alpha(2)-adrenergic receptors, and m3-muscarinic receptors. To determine the receptor(s) likely to be responsible for antipsychotic-drug-induced weight gain, we screened 17 typical and atypical antipsychotic drugs for binding to 12 neurotransmitter receptors. H(1)-histamine receptor affinities for this group of typical and atypical antipsychotic drugs were significantly correlated with weight gain (Spearman rho=-0.72; p<0.01), as were affinities for alpha(1A) adrenergic (rho=-0.54; p<0.05), 5-HT(2C) (rho=-0.49; p<0.05) and 5-HT(6) receptors (rho=-0.54; p<0.05), whereas eight other receptors' affinities were not. A principal components analysis showed that affinities at the H(1), alpha(2A), alpha(2B), 5-HT(2A), 5-HT(2C), and 5-HT(6) receptors were most highly correlated with the first principal component, and affinities for the D(2), 5-HT(1A), and 5-HT(7) receptors were most highly correlated with the second principal component. A discriminant functions analysis showed that affinities for the H(1) and alpha(1A) receptors were most highly correlated with the discriminant function axis. The discriminant function analysis, as well as the affinity for the H(1)-histamine receptor alone, correctly classified 15 of the 17 drugs into two groups; those that induce weight gain and those that do not. Because centrally acting H(1)-histamine receptor antagonists are known to induce weight gain with chronic use, and because H(1)-histamine receptor affinities are positively correlated with weight gain among typical and atypical antipsychotic drugs, it is recommended that the next generation of atypical antipsychotic drugs be screened to avoid H(1)-histamine receptors.
Kroeze
Wesley K
WK
Department of Biochemistry, RM W463, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4935, USA. wkk@po.cwru.edu
Hufeisen
Sandra J
SJ
Popadak
Beth A
BA
Renock
Sean M
SM
Steinberg
SeAnna
S
Ernsberger
Paul
P
Jayathilake
Karu
K
Meltzer
Herbert Y
HY
Roth
Bryan L
BL
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000378:metabolism*; D016002:Discriminant Analysis; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005544:Forecasting; D006801:Humans; D011485:Protein Binding / Q000502:physiology; D011969:Receptors, Histamine H1 / Q000378:metabolism*; D018709:Statistics, Nonparametric; D015430:Weight Gain / Q000187:drug effects* / Q000502:physiology*
D014150:Antipsychotic Agents; D011969:Receptors, Histamine H1